Invizius, a biotechnology company developing second generation therapies for a range of complement-driven autoimmune and inflammatory disorders, has recruited its 300th patient to the ‘Angry Blood’ study. This is a significant milestone in its novel kinetic study to identify patients with elevated complement responses during haemodialysis (HD), so-called ‘angry blood,’ who may have a […]
